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TO THE EDITOR
A recent genome-wide association
study (GWAS) conducted by Cargill
et al. (2007) reported an association
between psoriasis and the IL-12b and
IL-23R genes. Their study focused on
the analysis of gene-centric single
nucleotide polymorphisms (SNPs) iden-
tifying four non-HLA SNPs associated
with psoriasis in a North American
population. Our study confirms these
findings in a single-point association
study genotyping these four SNPs (two
in the IL-12b gene and two in the IL-
23R gene) in 597 UK psoriasis patients
with onset of disease at p40 years of
age (type I psoriasis; 53.6% male;
46.4% female; mean age of onset 19.8
years; 58.8% patients HLA-Cw6-posi-
tive). Recruitment of type I psoriasis
patients for the case cohort was co-
ordinated through the Dermatology
Centre, Hope Hospital, The University
of Manchester, Manchester, UK. All
patients gave written informed consent
and the study was approved by the
Salford and Trafford Local Research
Ethics Committee and conducted ac-
cording to the Declaration of Helsinki
Principles. Control data were available
from the Wellcome Trust Case Control
Consortium (rs6887695, rs11209026,
and rs7530511) and 1958 British Birth
Cohort study (rs3212227) (Power and
Elliott, 2006). The SNP rs3212227,
located in the IL-12b gene, which
encodes the IL-12b-p40 subunit of the
IL-12 and IL-23, was previously asso-
ciated with the disease in a study of 143
Japanese psoriasis patients and 100
unaffected controls (P¼ 0.035) (Tsunemi
et al., 2002) and also a recent indepen-
dent GWAS of UK psoriasis patients
(P¼0.036) (Capon et al., 2007). Our
findings replicate the associations
found in the US (P¼7.85 1010;
Cargill et al., 2007), Japanese, and UK
cohorts with association to the same
allele (P¼0.003; Table 1) where risk
was conferred by carriage of two copies
of the major allele (genotype AA) with
an odds ratio of 1.38 (95% CI
1.14–1.68; P¼ 0.0004).
The GWAS found association to a
second SNP rs6887695 in IL-12b
(Cargill et al., 2007) and reported a
haplotypic association. We also de-
tected association to rs6887695, con-
firming this single-point genotypic
association (P¼0.001; Table 1) on the
basis of a dominant model of inheri-
tance for the major allele (genotype
GG) with an odds ratio of 1.72 (95% CI
1.18–2.56; P¼0.0016); however, we
reported low linkage disequilibrium
correlation with r2¼ 0.21 (calculated
using the genetic analysis software
HelixTree; Golden Helix Inc., Boze-
man, Montana) between these SNPs in
the patient cohort and thus did not
conduct any haplotype analysis.
Cargill et al. (2007) also investigated
the IL-23 cytokine-related proteins (as
IL-23R shares the IL-12b-p40 protein
subunit) and identified two further SNPs
in the IL-23 receptor gene (IL-23R)
associated with psoriasis. SNP
rs7530511 was detected in the single-
point marker analysis of the GWAS
with a P-value of 0.006, whereas SNP
rs11209026 showed significant associa-
tion to the disease in combination with
this marker in an estimated haplotype
analysis (P¼ 3.3106) (Cargill et al.,
2007), a finding replicated in the
GWAS of UK psoriasis patients
(P¼0.00014) (Capon et al., 2007).
Our study also confirms genotypic
association to these markers with
Po0.001 and P¼ 0.001 for
rs11209026 and rs7530511 SNPs, re-
spectively (Table 1), with a dominant
model of inheritance for the major
allele in rs11209026 (genotype GG)
with odds ratio of 1.67 (95% CI
1.20–2.37; P¼0.0008) and risk con-
Abbreviations: GWAS, genome-wide association study; IL-23R, IL-23-receptor; SNP, single nucleotide
polymorphism.
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ferred by carriage of two copies of the
major allele in rs7530511 (genotype
CC) with odds ratio of 1.98 (95% CI
1.51–2.63; Po0.0001). However, again
we do not report any haplotype analysis
for these markers, as we found no
evidence of linkage disequilibrium cor-
relation between rs11209026 and
rs7530511 in the patient cohort
(r2o0.01, again calculated using the
HelixTree software). Interestingly, this
gene had previously shown significant
association to inflammatory bowel dis-
ease (Duerr et al., 2006), a condition
showing comorbidity with psoriasis
(prevalence of psoriasis 9.6% in inflam-
matory bowel disease patients com-
pared to 2.2% of controls; Lee et al.,
1990).
In summary, we have confirmed the
associations to SNPs in both IL-12b and
IL-23R detected in the GWAS of Cargill
et al. (2007). Reassuringly, the minor
allele frequencies for these SNPs are
very similar in the controls of all three
studies with the associations detected
assigned to the same allele of the
markers (Tsunemi et al., 2002; Capon
et al., 2007; Cargill et al., 2007).
Therefore, we conclude that IL-12b
and IL-23R are key non-HLA genes in
psoriasis and that further investigation
and functional studies are required to
determine how the variant forms of
these genes influence the pathogenesis
of the disease. It is interesting to note
evidence that both IL-12b and IL-23R
appear to play key roles in psoriasis.
This evidence includes the observations
that IL-23 induces epidermal hyperpro-
liferation via tumor necrosis factor-a
and IL-20 (Chan et al., 2006), and
suppressing the effects of IL-12/IL-23
with a monoclonal antibody to the
shared p40 subunit is effective treat-
ment for severe psoriasis (Krueger et al.,
2007). Investigations to elucidate the
precise mechanisms by which these
variants influence the psoriatic process
may lead to further developments of
novel therapeutics targeting this key
pathway.
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TO THE EDITOR
Molluscum contagiosum virus (MCV)
produces smooth, flesh-colored papules
with central umbilication. In HIV-
infected individuals, extensive and
recalcitrant MCV lesions are a thera-
peutic challenge. Meadows et al. (1997)
first described therapeutic success with
topical or intravenous cidofovir (CDV),
a nucleoside analog of deoxycytidine
monophosphate, for otherwise recalci-
trant MCV lesions in three AIDS
patients. Topical 1–3% CDV cream has
been highly efficacious in treating gene-
ralized MCV lesions, with successful
treatment of a boy with Wiskott–Aldrich
syndrome (Davies et al., 1999), two
HIV-infected children (Toro et al.,
2000), and two otherwise healthy chil-
dren (Zabawski and Cockerell, 1999).
Because MCV cannot be propagated
in tissue culture and does not infect
animals, overexpression of MCV DNA
polymerase is necessary to evaluate the
effects of CDV on viral DNA polymer-
ase activity. However, identifying a
successful overexpression system for
this enzyme has been difficult. Dorsky
and Crumpacker (1988) reported high
expression of herpes simplex virus-1
(HSV-1) DNA polymerase in E. coli,
but the recombinant protein was insolu-
ble and enzymatically inactive. Haffey
et al. (1988) successfully expressed
HSV-1 DNA polymerase in the yeast
Saccharomyces cerevisiae, but the ex-
tracts also contained the yeast a DNA
polymerase. McDonald and Traktman
(1994) found that vaccinia virus DNA
polymerase cannot be expressed in
E. coli due to extreme toxicity and
proteolysis or in S. cerevisiae due to
transcriptional termination within the
polymerase gene. To overcome these
technical issues, we selected an in vitro
transcription–translation system to ex-
press viral DNA polymerases, similar to
the successful expression systems for
HSV-1 DNA polymerase (Dorsky and
Crumpacker, 1988) and equine herpes-
virus 1 (Loregian et al., 2006).
We cloned the viral DNA polymer-
ase genes of MCV (MC39L), cowpox
virus (CPV) (CPXV75), and HSV-1
(UL30) into the T7 expression vector
pGEM-3Z (Promega, Madison, WI). Of
these,MC39L and CPXV75 are the most
closely related, with 53% identity and
72% similarity (Figure 1a). For MC39L,
a 3,159-bp AccIII–BstPI fragment span-
ning the complete MC39L from 12-bp
upstream of the ATG to 133-bp down-
stream of the TAG was inserted into
pGEM-3Z. For CPXV75, a PCR product
from 6-bp upstream of the ATG to
381 bp 50 of CPXV75 was generated
using primers 50-GGTACCTAGAAATG
GATGTTCGGTGC-30 (KpnI site, under-
lined) and 50-TCGTCCAACGAGTAACA
TCC-30, shortened to 362bp by KpnI–
EcoRV digestion, and cloned into the
KpnI–BamHI sites of pGEM-3Z along
with a 4,591-bp EcoRV–BamHI fragment
containing 2,664bp 30 of CPXV75. For
UL30, 524bp 50 of UL30 was amplified
with primers 50-GAATTCATGTTTTCCG
GTGGCGGCGG-30 (EcoRI site, under-
lined) and 50-ATGGCGTCCATAAACCG
CGC-30, shortened to 482bp by EcoRI–-
SphI digestion, and inserted into the
EcoRI–SphI site of pGEM-3Z along with
a 3,760-bp SphI fragment containing
3,227bp 30 of UL-30.
The cloned DNA polymerase genes
were transcribed with T7 RNA
polymerase and translated in rabbit
reticulocyte lysates (Promega). Poly-
merases synthesized in the presence of
[35S]methionine were visualized by
electrophoresis (Figure 1b). DNA poly-
merase assays were performed in 100 ml
volumes containing 10 mg of activated
calf thymus DNA, 100mM ammonium
sulfate, 50mM Tris–hydrochloride (pH
8.0), 50 mg of BSA, 0.5mM dithiothre-
itol, 7.5mM MgCl2, 5 mM each of dCTP,
dGTP, and dTTP, and 2.5mCi of [32P]
dATP (3,000CimM1) as described
(Dorsky and Crumpacker, 1988). The
incorporation of [32P]dATP by the pro-
grammed reticulocyte lysates increased
linearly with time up to 20minutes
(Figure 2). In contrast, the endogenous
polymerase activity of the control
reticulocyte lysates without mRNA re-
mained near the filter background level
(data not shown).
Once taken up by cells, CDV is
converted to a diphosphate (CDVpp)
and acts as a competitive inhibitor
of viral DNA polymerases. The effects
of CDVpp (Trilink Biotechnologies,
San Diego, CA) on viral DNA poly-
merases were examined using 30 ml
of reticulocyte lysates programmed
with 8 mg of transcripts for each viral
DNA polymerase gene. MCV, CPV, and
Abbreviations: CDV, cidofovir; CDVpp, cidofovir diphosphate; CPV, cowpox virus; HSV, herpes simplex
virus; MCV, molluscum contagiosum virus
www.jidonline.org 1327
T Watanabe and K Tamaki
MCV and CDV
